Adenosine-Mediated Effects of Ticagrelor
Key result
Ticagrelor increases adenosine activity at ischemic sites by inhibiting the ENT1 transporter.
Why the study?
Understanding the mode of action of ticagrelor is of interest because its clinical profile, in terms of efficacy and adverse events, differs from that of thienopyridine P2Y12 antagonists.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Mechanistic basis for ticagrelor’s profile; leaves open whether ENT1 inhibition alters net clinical outcomes versus other P2Y12 inhibitors.
Key Points
- To critically evaluate published evidence describing the secondary mechanism of action of the P2Y12 receptor antagonist ticagrelor mediated through adenosine regulation.
- Critical narrative review of pharmacological and biochemical literature on ticagrelor mechanisms.
- Evaluation of studies examining type 1 equilibrative nucleoside transporter (ENT1) function and cellular adenosine metabolism.
- Comparative analysis of ticagrelor's clinical pharmacology against thienopyridine-class P2Y12 antagonists.
- Ticagrelor inhibits the ENT1 adenosine transporter, which shields extracellular adenosine from intracellular uptake and metabolic degradation.
- Inhibition leads to increased local concentrations and enhanced biological activity of adenosine, preferentially at sites of ischemia and tissue injury.
- This secondary mechanism provides a biological rationale for clinical differences in efficacy and adverse event profiles between ticagrelor and thienopyridine inhibitors.
PICO
I
Intervention / Comparator
Ticagrelor vs Thienopyridine P2Y12 antagonists
Cite This Study
Cattaneo et al. (2014) reported a review. Ticagrelor vs. Thienopyridine P2Y12 antagonists was evaluated. Ticagrelor exerts an additional mode of action by inhibiting the adenosine transporter ENT1, increasing adenosine concentration and biological activity at sites of ischemia and tissue injury.